Filing Details

Accession Number:
0000899243-21-040769
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-20 16:33:28
Reporting Period:
2021-10-18
Accepted Time:
2021-10-20 16:33:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1521036 Lantheus Holdings Inc. LNTH In Vitro & In Vivo Diagnostic Substances (2835) 352318913
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1861389 Etienne Montagut C/O Lantheus Holdings, Inc.
331 Treble Cove Road
North Billerica MA 01862
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-10-18 2,364 $22.90 85,342 No 4 S Direct
Common Stock Disposition 2021-10-19 1,748 $22.95 83,594 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transaction reported in this Form 4 was effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.
  2. Includes 440 shares acquired under the LNTH employee stock purchase plan on September 23, 2021.
  3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 5, 2021.